Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2

@article{ArenasRamirez2016ImprovedCI,
  title={Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2},
  author={Natalia Arenas-Ramirez and Chao Zou and Simone Popp and Daniel Zingg and Barbara Brannetti and Emmanuelle Wirth and Thomas Calzascia and Jiri Kovarik and Lukas Sommer and Gerhard Zenke and Janine Woytschak and Catherine H. R{\'e}gnier and Andreas G. Katopodis and Onur Boyman},
  journal={Science Translational Medicine},
  year={2016},
  volume={8},
  pages={367ra166-367ra166}
}
Interleukin-2 (IL-2) immunotherapy is an attractive approach in treating advanced cancer. However, by binding to its IL-2 receptor α (CD25) subunit, IL-2 exerts unwanted effects, including stimulation of immunosuppressive regulatory T cells (Tregs) and contribution to vascular leak syndrome. We used a rational approach to develop a monoclonal antibody to human IL-2, termed NARA1, which acts as a high-affinity CD25 mimic, thereby minimizing association of IL-2 with CD25. The structure of the IL… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 41 references

Interleukin-2: Biology, Design and Application.

Trends in immunology • 2015
View 16 Excerpts
Highly Influenced

Expect the unexpected

D. Marvel, D. I. Gabrilovich, Myeloid-derived suppressor cells in the tumor microenvironment
J. Clin. Invest. 125, 3356–3364 • 2015